{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-303895","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2025-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.028966+00:00","generated_at":"2026-05-16T15:57:40.354119+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"medium","headline":"Perspective Therapeutics updates corporate presentation; highlights pipeline progress","bullets":["Updated presentation covers [212Pb]VMT-α-NET Phase 1/2a for NETs and [212Pb]VMT01 for melanoma.","Claims compelling anti-tumor activity, durable disease control, and best-in-class safety for NET trial.","Presentation notes upcoming data milestones but no specific dates or new financial guidance.","Pipeline includes PSV359 targeting FAP-α; supply chain with on-demand regional sites.","No material changes to business or financials disclosed in the 8-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-303895","json":"https://secwatch.observer/filing/0001193125-25-303895.json","markdown":"https://secwatch.observer/filing/0001193125-25-303895.md","text":"https://secwatch.observer/filing/0001193125-25-303895.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312525303895/0001193125-25-303895-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312525303895/catx-20251201.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:57:40.354119+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}